|
1
|
Walcott BP, Nahed BV, Mohyeldin A, Coumans
JV, Kahle KT and Ferreira MJ: Chordoma: Current concepts,
management, and future directions. Lancet Oncol. 13:e69–e76.
2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ropper AE, Cahill KS, Hanna JW, McCarthy
EF, Gokaslan ZL and Chi JH: Primary vertebral tumors: A review of
epidemiologic, histological and imaging findings, part II: Locally
aggressive and malignant tumors. Neurosurgery. 70:211–219.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chambers KJ, Lin DT, Meier J,
Remenschneider A, Herr M and Gray ST: Incidence and survival
patterns of cranial chordoma in the United States. Laryngoscope.
124:1097–1102. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
McMaster ML, Goldstein AM, Bromley CM,
Ishibe N and Parry DM: Chordoma: Incidence and survival patterns in
the United States, 1973-1995. Cancer Causes Control. 12:1–11.
2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sciubba DM, Chi JH, Rhines LD and Gokaslan
ZL: Chordoma of the spinal column. Neurosurg Clin N Am. 19:5–15.
2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Jahangiri A, Jian B, Miller L, El-Sayed IH
and Aghi MK: Skull base chordomas: Clinical features, prognostic
factors, and therapeutics. Neurosurg Clin N Am. 24:79–88.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chugh R, Tawbi H, Lucas DR, Biermann JS,
Schuetze SM and Baker LH: Chordoma: The non sarcoma primary bone
tumor. Oncologist. 12:1344–1350. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fuchs B, Dickey ID, Yaszemski MJ, Inwards
CY and Sim FH: Operative management of sacral chordoma. J Bone
Joint Surg Am. 87:2211–2216. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bongers MER, Dea N, Ames CP and Schwab JH:
Surgical strategies for chordoma. Neurosurg Clin N Am. 31:251–261.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
D'Amore T, Boyce B and Mesfin A: Chordoma
of the mobile spine and sacrum: Clinical management and prognosis.
J Spine Surg. 4:546–552. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Alan O, Akin Telli T, Ercelep O, Tanrikulu
Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül
Babacan N, Dane F and Yumuk PF: Chordoma: A case series and review
of the literature. J Med Case Rep. 12(239)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Vellutini EAS, Brock RS, Martins HO,
Taricco MA and de Oliveira MF: Diffuse spinal spreading following
previous intracranial intradural chordoma resection: A rare case
report. J Clin Neurosci. 64:44–46. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Akmansu M, Kurt G, Demircan V and Senturk
E: Results of chordoma patients treated by different approaches in
a single institution. Turk Neurosurg. 30:366–370. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ahmed R, Sheybani A, Menezes AH, Buatti JM
and Hitchon PW: Disease outcomes for skull base and spinal
chordomas: A single center experience. Clin Neurol Neurosurg.
130:67–73. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pu F, Wang B, Liu J, Chen F and Shao Z:
Giant chordoma in the thoracolumbar spine: A case report and
literature review. Eur Spine J. 26 (Suppl 1):S95–S99.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Colangeli S, Muratori F, Bettini L, Frenos
F, Totti F, D'Arienzo A, Campo FR, Scoccianti G, Beltrami G,
Campanacci DA and Capanna R: Surgical treatment of sacral chordoma:
En bloc resection with negative margins is a determinant of the
long-term outcome. Surg Technol Int. 33:343–348. 2018.PubMed/NCBI
|
|
17
|
Niu XH: Interpretation of 2020 NCCN
clinical practice guidelines in oncology-bone cancer. Zhonghua Wai
Ke Za Zhi. 58:430–434. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
18
|
Ruggieri P, Angelini A, Ussia G, Montalti
M and Mercuri M: Surgical margins and local control in resection of
sacral chordomas. Clin Orthop Relat Res. 468:2939–2947.
2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mohanty S, Pai Kanhangad M and Kundangar
R: The extended posterior approach for resection of sacral tumours.
Eur Spine J. 28:1461–1467. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yang Y, Li Y, Liu W, Xu H and Niu X: The
clinical outcome of recurrent sacral chordoma with further surgical
treatment. Medicine (Baltimore). 97(e13730)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kabolizadeh P, Chen YL, Liebsch N,
Hornicek FJ, Schwab JH, Choy E, Rosenthal DI, Niemierko A and
DeLaney TF: Updated outcome and analysis of tumor response in
mobile spine and sacral chordoma treated with definitive high-dose
photon/proton radiation therapy. Int J Radiat Oncol Biol Phys.
97:254–262. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Imai R, Kamada T, Tsuji H, Sugawara S,
Serizawa I, Tsujii H and Tatezaki S: Working Group for Bone and
Soft Tissue Sarcomas. Effect of carbon ion radiotherapy for sacral
chordoma: Results of Phase I-II and Phase II clinical trials. Int J
Radiat Oncol Biol Phys. 77:1470–1476. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Park L, Delaney TF, Liebsch NJ, Hornicek
FJ, Goldberg S, Mankin H, Rosenberg AE, Rosenthal DI and Suit HD:
Sacral chordomas: Impact of high-dose proton/photon-beam radiation
therapy combined with or without surgery for primary versus
recurrent tumor. Int J Radiat Oncol Biol Phys. 65:1514–1521.
2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chen YL, Liebsch N, Kobayashi W, Goldberg
S, Kirsch D, Calkins G, Childs S, Schwab J, Hornicek F and DeLaney
T: Definitive high-dose photon/proton radiotherapy for unresected
mobile spine and sacral chordomas. Spine (Phila Pa 1976).
38:E930–E936. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bompas E, Le Cesne A, Tresch-Bruneel E,
Lebellec L, Laurence V, Collard O, Saada-Bouzid E, Isambert N, Blay
JY, Amela EY, et al: Sorafenib in patients with locally advanced
and metastatic chordomas: a phase II trial of the French Sarcoma
Group (GSF/GETO). Ann Oncol. 26:2168–2173. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lebellec L, Bertucci F, Tresch-Bruneel E,
Bompas E, Toiron Y, Camoin L, Mir O, Laurence V, Clisant S,
Decoupigny E, et al: Circulating vascular endothelial growth factor
(VEGF) as predictive factor of progression-free survival in
patients with advanced chordoma receiving sorafenib: An analysis
from a phase II trial of the French sarcoma group (GSF/GETO).
Oncotarget. 7:73984–73994. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Stacchiotti S, Longhi A, Ferraresi V,
Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti
S, Messina A, et al: Phase II study of imatinib in advanced
chordoma. J Clin Oncol. 30:914–920. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
George S, Merriam P, Maki RG, Van den
Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM,
D'Adamo DR, et al: Multicenter phase II trial of sunitinib in the
treatment of nongastrointestinal stromal tumor sarcomas. J Clin
Oncol. 27:3154–3160. 2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Stacchiotti S, Marrari A, Tamborini E,
Palassini E, Virdis E, Messina A, Crippa F, Morosi C, Gronchi A,
Pilotti S and Casali PG: Response to imatinib plus sirolimus in
advanced chordoma. Ann Oncol. 20:1886–1894. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Meng T, Jin J, Jiang C, Huang R, Yin H,
Song D and Cheng L: Molecular targeted therapy in the treatment of
chordoma: A systematic review. Front Oncol. 9(30)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu C, Jia Q, Wei H, Yang X, Liu T, Zhao
J, Ling Y, Wang C, Yu H, Li Z, et al: Apatinib in patients with
advanced chordoma: A single-arm, single-centre, phase 2 study.
Lancet Oncol. 21:1244–1252. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Stacchiotti S and Sommer J: Chordoma
Global Consensus Group. Building a global consensus approach to
chordoma: A position paper from the medical and patient community.
Lancet Oncol. 16:e71–e83. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Stacchiotti S, Gronchi A, Fossati P,
Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S,
Bruzzi P, et al: Best practices for the management of
local-regional recurrent chordoma: A position paper by the chordoma
global consensus group. Ann Oncol. 28:1230–1242. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Colia V and Stacchiotti S: Medical
treatment of advanced chordomas. Eur J Cancer. 83:220–228.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ji T, Guo W, Yang R, Tang X, Wang Y and
Huang L: What are the conditional survival and functional outcomes
after surgical treatment of 115 patients with sacral chordoma? Clin
Orthop Relat Res. 475:620–630. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yang Y, Niu X, Li Y, Liu W and Xu H:
Recurrence and survival factors analysis of 171 cases of sacral
chordoma in a single institute. Eur Spine J. 26:1910–1916.
2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhou J, Sun J, Bai HX, Huang X, Zou Y, Tan
X, Zhang Z, Tang X, Tao Y, Xiao B, et al: Prognostic factors in
patients with spinal chordoma: An integrative analysis of 682
patients. Neurosurgery. 81:812–823. 2017.PubMed/NCBI View Article : Google Scholar
|
